[ { "@graph" : [ { "@id" : "http://purl.org/np/RAymPzHleRaxxoSGl85qjP2e8Xbx6kETXMYV-2rrvg59g", "@type" : [ "http://www.nanopub.org/nschema#Nanopublication" ], "http://www.nanopub.org/nschema#hasAssertion" : [ { "@id" : "http://purl.org/np/RAymPzHleRaxxoSGl85qjP2e8Xbx6kETXMYV-2rrvg59g#assertion" } ], "http://www.nanopub.org/nschema#hasProvenance" : [ { "@id" : "http://purl.org/np/RAymPzHleRaxxoSGl85qjP2e8Xbx6kETXMYV-2rrvg59g#provenance" } ], "http://www.nanopub.org/nschema#hasPublicationInfo" : [ { "@id" : "http://purl.org/np/RAymPzHleRaxxoSGl85qjP2e8Xbx6kETXMYV-2rrvg59g#pubinfo" } ] } ], "@id" : "http://purl.org/np/RAymPzHleRaxxoSGl85qjP2e8Xbx6kETXMYV-2rrvg59g#Head" }, { "@graph" : [ { "@id" : "http://purl.obolibrary.org/obo/DOID_437", "https://w3id.org/biolink/vocab/category" : [ { "@id" : "https://w3id.org/biolink/vocab/Disease" } ] }, { "@id" : "http://purl.org/np/RAymPzHleRaxxoSGl85qjP2e8Xbx6kETXMYV-2rrvg59g#association", "@type" : [ "http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement" ], "http://www.w3.org/1999/02/22-rdf-syntax-ns#object" : [ { "@id" : "http://purl.obolibrary.org/obo/DOID_437" } ], "http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate" : [ { "@id" : "https://w3id.org/biolink/vocab/treats" } ], "http://www.w3.org/1999/02/22-rdf-syntax-ns#subject" : [ { "@id" : "https://identifiers.org/drugbank:DB00468" } ], "http://www.w3.org/2000/01/rdf-schema#label" : [ { "@value" : "\"Quinine sulfate is contraindicated in patients with the following: Prolongation of QT interval ( 4 Glucose-6-phosphate dehydrogenase (G6PD) deficiency ( 4 Myasthenia gravis ( 4 Known hypersensitivity to quinine, mefloquine, or quinidine ( 4 Optic neuritis ( 4 Quinine sulfate is contraindicated in patients with the following: * Prolonged QT interval. One case of a fatal ventricular arrhythmia was reported in an elderly patient with a prolonged QT interval at baseline, who received quinine sulfate intravenously for P. falciparum [see WARNINGS AND PRECAUTIONS ( 5.3 * Glucose-6-phosphate dehydrogenase (G6PD) deficiency. * Hemolysis can occur in patients with G6PD deficiency receiving quinine. * Known hypersensitivity reactions to quinine. * These include, but are not limited to, the following [see WARNINGS AND PRECAUTIONS ( 5.6 * Thrombocytopenia * Idiopathic thrombocytopenia purpura (ITP) and Thrombotic thrombocytopenic purpura (TTP) * Hemolytic uremic syndrome (HUS) * Blackwater fever (acute intravascular hemolysis, hemoglobinuria, and hemoglobinemia) * Known hypersensitivity to mefloquine or quinidine: cross-sensitivity to quinine has been documented [see WARNINGS AND PRECAUTIONS ( 5.6 * Myasthenia gravis. Quinine has neuromuscular blocking activity, and may exacerbate muscle weakness. * Optic neuritis. Quinine may exacerbate active optic neuritis [see ADVERSE REACTIONS ( 6\"" } ], "https://w3id.org/biolink/vocab/provided_by" : [ { "@id" : "https://w3id.org/um/NeuroDKG" } ], "https://w3id.org/biolink/vocab/relation" : [ { "@id" : "https://schema.org/MedicalContraindication" } ] }, { "@id" : "https://identifiers.org/drugbank:DB00468", "https://w3id.org/biolink/vocab/category" : [ { "@id" : "https://w3id.org/biolink/vocab/Drug" } ] } ], "@id" : "http://purl.org/np/RAymPzHleRaxxoSGl85qjP2e8Xbx6kETXMYV-2rrvg59g#assertion" }, { "@graph" : [ { "@id" : "http://purl.org/np/RAymPzHleRaxxoSGl85qjP2e8Xbx6kETXMYV-2rrvg59g#assertion", "http://www.w3.org/ns/prov#wasAttributedTo" : [ { "@id" : "https://orcid.org/0000-0002-1468-3557" } ] } ], "@id" : "http://purl.org/np/RAymPzHleRaxxoSGl85qjP2e8Xbx6kETXMYV-2rrvg59g#provenance" }, { "@graph" : [ { "@id" : "http://purl.org/np/RAymPzHleRaxxoSGl85qjP2e8Xbx6kETXMYV-2rrvg59g", "http://purl.org/dc/terms/created" : [ { "@type" : "http://www.w3.org/2001/XMLSchema#dateTime", "@value" : "2021-08-23T18:44:18.224+02:00" } ], "http://purl.org/dc/terms/creator" : [ { "@id" : "https://orcid.org/0000-0002-1468-3557" } ], "https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate" : [ { "@id" : "http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM" } ], "https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate" : [ { "@id" : "http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM" } ], "https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate" : [ { "@id" : "http://purl.org/np/RAhNHZw6Urw_Mccs4qy6Ws3C9CRuaHpQx8AwuApbWkqnY" } ] }, { "@id" : "http://purl.org/np/RAymPzHleRaxxoSGl85qjP2e8Xbx6kETXMYV-2rrvg59g#sig", "http://purl.org/nanopub/x/hasAlgorithm" : [ { "@value" : "RSA" } ], "http://purl.org/nanopub/x/hasPublicKey" : [ { "@value" : "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB" } ], "http://purl.org/nanopub/x/hasSignature" : [ { "@value" : "T3N3TGK5kHu+neLOtZXrtOnpSw3grcBqr1rVJrHngOeardHubJl2iz+jiYJ8cgDP9/IiglORHW1fpPFWcjjz+QIwrLDtmxl9ORr30gi+JcjE+QHuVh/QNeZCFlfK/GrE32Gig9oSpEvtA1qVESS+9oyxeuts3EJg0u9U+qdz2KY=" } ], "http://purl.org/nanopub/x/hasSignatureTarget" : [ { "@id" : "http://purl.org/np/RAymPzHleRaxxoSGl85qjP2e8Xbx6kETXMYV-2rrvg59g" } ] } ], "@id" : "http://purl.org/np/RAymPzHleRaxxoSGl85qjP2e8Xbx6kETXMYV-2rrvg59g#pubinfo" } ]